Kymera Therapeutics (NASDAQ:KYMR) Shares Down 4.7% After Insider Selling

Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Free Report)’s share price was down 4.7% during mid-day trading on Wednesday following insider selling activity. The stock traded as low as $37.01 and last traded at $37.57. Approximately 87,663 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 670,656 shares. The stock had previously closed at $39.44.

Specifically, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Joanna Horobin sold 8,500 shares of Kymera Therapeutics stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $32.99, for a total value of $280,415.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the sale, the director now owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The disclosure for this sale can be found here. Insiders sold 479,200 shares of company stock valued at $18,219,660 over the last ninety days. 15.82% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. B. Riley lifted their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $46.00 price objective on shares of Kymera Therapeutics in a research report on Monday, June 17th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a research report on Wednesday. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $42.09.

View Our Latest Analysis on Kymera Therapeutics

Kymera Therapeutics Trading Down 8.1 %

The business has a 50 day moving average of $33.79 and a two-hundred day moving average of $34.63. The firm has a market cap of $2.22 billion, a P/E ratio of -14.44 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. During the same period in the prior year, the firm posted ($0.70) EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.86 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in shares of Kymera Therapeutics during the 4th quarter worth $78,000. Comerica Bank raised its position in shares of Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after acquiring an additional 295 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Kymera Therapeutics during the first quarter worth about $207,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Kymera Therapeutics by 352.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock worth $164,000 after purchasing an additional 5,002 shares during the period.

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Featured Articles

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.